TARA Protara Therapeutics, Inc.

8-K Current Report

Filed: February 24, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Protara Therapeutics, Inc. (TARA) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Standard Reg FD "furnished not filed" disclaimer — no investor-actionable content disclosed in this section

Item 8.01 · Other Events

• BCG-Unresponsive cohort: 65.7% CR at any time; 68.2% CR at 6 months; 100% of 12-month responders maintained CR through month 12
• BCG-Naïve cohort: stronger durability — 72.4% CR at any time; 57.9% CR at 12 months; 100% (11/11) maintained CR from months 9–12

+3 more insights

Other Protara Therapeutics, Inc. 8-K Filings

8-K Mar 10, 2026

Get deeper insights on Protara Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.